跳至主要内容
临床试验/ISRCTN15731357
ISRCTN15731357已完成2 期

A randomised, blinded placebo-controlled Phase 2a study to evaluate the safety and efficacy of Artesunate treatment in severely injured trauma patients with traumatic haemorrhage.

Queen Mary University of London0 个研究点目标入组 105 人开始时间: 2015年8月28日最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
105

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Adult trauma patients (16 years and above).
  • 2. Activation of the local massive haemorrhage protocol
  • 3. Patients with active, ongoing haemorrhage
  • 4. Agreement for participation is provided on behalf of incapacitated patients by Personal Consultee or Nominated Consultee (i.e. trauma team leader)

排除标准

  • 1. Time of admission more than 2 hours after the time of injury
  • 2. Time of drug administration not attainable within 4 hours of injury
  • 3. Subject not expected to survive more than 48 hours
  • 4. Evidence of severe traumatic brain injury (GCS 3 at scene)
  • 5. Known pregnancy
  • 6. Suspected non-haemorrhagic cause of shock
  • 7. Massive haemorrhage protocol activation more than one hour after arrival
  • 8. Concurrent participation in another Clinical Trial of an IMP
  • 9. Breastfeeding females
  • 10. Known allergy to Artesunate

研究者

相似试验